BHVN icon

Biohaven
BHVN

Upgrade to unlock
Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 90.3%
Negative

Positive
MarketBeat
11 days ago
Biohaven Insiders Bet $33 Million on a Turnaround
When corporate executives make multi-million-dollar personal investments in the company they lead, it is one of the most potent signals an investor can receive. At Biohaven NYSE: BHVN, that signal has just been sent loud and clear.
Biohaven Insiders Bet $33 Million on a Turnaround
Neutral
The Motley Fool
11 days ago
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy?
On November 17, 2025, Biohaven's Chief Accounting Officer, George Clark, acquired 17,000 shares of company stock. Mr. Clark's purchase was valued at approximately $144,800.
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy?
Neutral
PRNewsWire
17 days ago
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
NEW HAVEN, Conn. , Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
Positive
Seeking Alpha
18 days ago
Biohaven Q3 Earnings: Falling Back To Earth With A Thud
Biohaven (BHVN) narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending and steep share price declines. BHVN's pipeline includes Opakalim for depression and epilepsy, TRAP/MoDE degraders for IgA nephropathy and Graves' disease, and Taldefgrobep alfa for obesity and spinal muscular atrophy. Despite intriguing science and large market opportunities, clinical progress has been slow, with limited compelling data and stiff competition in target indications.
Biohaven Q3 Earnings: Falling Back To Earth With A Thud
Negative
Benzinga
19 days ago
FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Wednesday.
FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Neutral
PRNewsWire
19 days ago
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
NEW HAVEN, Conn. , Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
Neutral
PRNewsWire
19 days ago
Biohaven Announces Proposed Public Offering of Common Shares
NEW HAVEN, Conn. , Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Proposed Public Offering of Common Shares
Neutral
PRNewsWire
21 days ago
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
NEW HAVEN, Conn. , Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
Negative
Benzinga
26 days ago
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection
Biohaven Ltd. (NYSE:BHVN) stock plummeted on Wednesday, reaching its 52-week low, according to data from Benzinga Pro.
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection
Negative
Reuters
26 days ago
Biohaven shares plunge after US FDA declines to approve brain disorder drug
Shares of Biohaven fell more than 40% on Wednesday after the U.S. Food and Drug Administration declined to approve its experimental treatment for a rare brain disorder.
Biohaven shares plunge after US FDA declines to approve brain disorder drug
See News Rankings